Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up ; volume:12 ; number:1 ; year:2021 ; pages:186-192 ; extent:7
Case reports in ophthalmology ; 12, Heft 1 (2021), 186-192 (gesamt 7)
- Creator
-
Matsou, Artemis
Dermenoudi, Maria
Tzetzi, Despina
Rotsos, Tryfon
Makri, Olga
Anastasopoulos, Eleftherios
Symeonidis, Chrysanthos
- DOI
-
10.1159/000512579
- URN
-
urn:nbn:de:101:1-2021051301154098722298
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Matsou, Artemis
- Dermenoudi, Maria
- Tzetzi, Despina
- Rotsos, Tryfon
- Makri, Olga
- Anastasopoulos, Eleftherios
- Symeonidis, Chrysanthos
Other Objects (12)
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Subretinal peripapillary biopsy-proven sarcoidosis: a case report
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Subretinal peripapillary biopsy-proven sarcoidosis: a case report
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Subretinal peripapillary biopsy-proven sarcoidosis: a case report
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept